Health Canada has given the green light to Moderna’s bivalent COVID-19 vaccine, making it the first vaccine specifically targeting the Omicron variant to get approval for the Canadian market.
According to the drug authorization listing, the bivalent booster will be a half-dose of the amount delivered in the primary doses of the vaccine, keeping it in line with the dose delivered in boosters so far.
The Omicron booster is authorized only for Canadians over the age of 18 at this time.
Health Canada’s chief medical advisor Dr. Supriya Sharma said Thursday that the vaccine has been proven, in clinical studies, to have “strong” immune response to the original coronavirus that causes COVID-19 and B.A.1 – the original Omicron subvariant.
The vaccine does not specifically target the B.A.4 and B.A.5 subvariants that are now the dominant strains, but Sharma says clinical data shows a “good” response to those variants as well.
For more info, please go to [ Ссылка ]
Subscribe to Global News Channel HERE: [ Ссылка ]
Like Global News on Facebook HERE: [ Ссылка ]
Follow Global News on Twitter HERE: [ Ссылка ]
Follow Global News on Instagram HERE: [ Ссылка ]
#GlobalNews #coronavirus #covid19vaccine
